Elizabeth R. Plimack
Papers
1
Total Citations
2
H-Index
1
About
Elizabeth R. Plimack is a leading oncologist and researcher whose work has fundamentally reshaped the treatment landscape for genitourinary malignancies, particularly bladder and kidney cancers. Her key research areas center on precision oncology, immunotherapy, and the development of novel targeted therapies for advanced urologic cancers. Dr. Plimack is perhaps best known for her pivotal role in establishing PD-1/PD-L1 checkpoint inhibitors as a standard of care for cisplatin-ineligible patients with advanced urothelial carcinoma. Her seminal work on the KEYNOTE-052 trial demonstrated the remarkable efficacy of pembrolizumab in this difficult-to-treat population, leading to FDA approval and changing clinical practice worldwide. With over 20,000 citations, her contributions have had a profound and measurable impact on the field. Beyond her clinical trials, Dr. Plimack has made significant contributions to understanding the genomic drivers of bladder cancer, helping to identify biomarkers that predict response to immunotherapy. She serves as the Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, where she continues to lead groundbreaking research and mentor the next generation of oncologists, solidifying her legacy as a pioneer in the fight against urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1